Eleanor Perfetto Joins CMTP Board of Directors
BALTIMORE, June 9, 2014 /PRNewswire-USNewswire/ — The Center for Medical Technology Policy (CMTP) welcomes Dr. Eleanor Perfetto, a Professor of Pharmaceutical Health Services Research, at the University of Maryland School of Pharmacy, to their Board of Directors. Dr. Perfetto joins Mark Gibson of the Center for Evidence-Based Policy, Peter Mazonson of ClearCost Health, Lawrence Sadwin, and CMTP CEO Sean Tunis as CMTP’s current board members.
“It’s really now, more than ever, that the work of CMTP is at the heart of critical healthcare policy issues,” says Dr. Perfetto. “Better evidence for better health care decision making is a win-win for all stakeholders. I am so pleased to join the CMTP Board and to be actively involved in its work.”
Prior to joining the University of Maryland School of Pharmacy in 2013, Dr. Perfetto was the Senior Director, Federal Government Relations with Pfizer, Inc. She also currently serves as a Pharmacy Quality Alliance (PQA) board member and is the current co-chair of the National Quality Forum’s (NQF) Alzheimer’s Disease and Related Dementias Project.
“CMTP is honored to welcome Eleanor to our board of directors,” says Sean Tunis, CEO of CMTP. “She has been a tremendous supporter of CMTP since its inception and her expertise in comparative effectiveness research and patient advocacy make her a valuable addition to our board.”
The Center for Medical Technology Policy (CMTP) is an independent, non-profit 501(c)(3) organization that aims to make health care more effective and affordable by improving the quality, relevance, and efficiency of health care research. We focus on the design and implementation of comparative effectiveness research to produce information that helps patients, clinicians, and payers make informed treatment and policy decisions. CMTP provides a trusted forum in which a broad range of stakeholders can collaborate to identify important research questions, design appropriate studies, and develop innovative partnerships to implement these studies.
SOURCE Center for Medical Technology Policy